Medindia

X

Perrigo Announces Approval for Over-the-Counter Children's Cetirizine Oral Solution

Tuesday, April 15, 2008 General News J E 4
Advertisement
ALLEGAN, Mich., April 14 Perrigo Company(Nasdaq: PRGO; TASE) today announced that it has received final approval fromthe U.S. Food and Drug Administration to manufacture and marketover-the-counter (OTC) Children's Cetirizine Hydrochloride Oral Solution(Allergy) and Children's Cetirizine Hydrochloride Oral Solution(Hives-Relief), 1mg/mL.

The product will be marketed under store brand labels and is comparable toMcNeil Consumer Healthcare's Children's Zyrtec(R) Oral Solution, 1mg/mL,indicated for indoor and outdoor allergy and hives relief. According toWolters Kluwer data, brand sales for the original prescription strengthversion of the product for the last 12 months ending December 2007 wereapproximately $80 million.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This approval reflectsour strategy to be first to market with the important products that makequality healthcare more affordable for our customers."

The Company expects to begin shipping the product immediately.

Perrigo Company is a leading global healthcare supplier that develops,manufactures and distributes over-the-counter (OTC) and prescriptionpharmaceuticals, nutritional products, active pharmaceutical ingredients (API)and consumer products. The Company is the world's largest manufacturer of OTCpharmaceutical products for the store brand market. The Company's primarymarkets and locations of manufacturing facilities are the United States,Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet(http://www.perrigo.com).

Note: Certain statements in this press release are forward-lookingstatements within the meaning of Section 21E of the Securities Exchange Act of1934, as amended, and are subject to the safe harbor created thereby. Thesestatements relate to future events or the Company's future financialperformance and involve known and unknown risks, uncertainties and otherfactors that may cause the actual results, levels of activity, performance orachievements of the Company or its industry to be materially different fromthose expressed or implied by any forward-looking statements. In some cases,forward-looking statements can be identified by terminology such as "may,""will," "could," "would," "should," "expect," "plan," "anticipate," "intend,""believe," "estimate," "predict," "potential" or other comparable terminology.The Company has based these forward-looking statements on its currentexpectations, assumptions, estimates and projections. While the Companybelieves these expectations, assumptions, estimates and projections arereasonable, such forward-looking statements are only predictions and involveknown and unknown risks and uncertainties, many of which are beyond theCompany's control. These and other important factors, including thosediscussed under "Risk Factors" in the Company's Form 10-K for the year endedJune 30, 2007, as well as the Company's subsequent filings with the Securitiesand Exchange Commission, may cause actual results, performance or achievementsto differ materially from those expressed or implied by these forward-lookingstatements. The forward-looking statements in this press release are madeonly as of the date hereof, and unless otherwise required by applicablesecurities laws, the Company disclaims any intention or obligation to updateor revise any forward-looking statements, whether as a result of newinformation, future events or otherwise.

SOURCE Perrigo Company
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Poniard Pharmaceuticals and AltheaDx Sign Agreemen...
S
Free Fastin Weight Loss Pills Offered by Fastin.or...